AI Insight
A clinical trial (NRG-GI003) comparing proton therapy to photon therapy for treating advanced hepatocellular carcinoma found no survival advantage with proton therapy. The study was stopped early at interim analysis after crossing the futility boundary, meaning it was unlikely to show benefit even if continued. Proton therapy failed to improve overall survival, progression-free survival, or local progression rates compared to standard photon radiation therapy.
Why it matters
This finding is significant because proton therapy is considerably more expensive than conventional photon radiation therapy, and these results do not support its use for advanced liver cancer patients. The study provides important evidence to guide treatment decisions and healthcare resource allocation for hepatocellular carcinoma management.
Understand the Science
Initial results of the NRG Oncology NRG-GI003 clinical study comparing proton and photon therapy for patients with advanced hepatocellular carcinoma (HCC) indicate that proton therapy did not improve the primary objective of overall survival (OS). At the planned interim analysis, the trial was released for reporting after it crossed the futility boundary. Proton therapy also did not improve the trial’s secondary endpoints, including progression-free survival (PFS) and local progression (LP).